Aktienanalyse zu Lunai Bioworks Inc (LNAI)LNAILunai Bioworks Inc

Lunai Bioworks, Inc is focused on AI-powered biodefense, drug discovery and advanced diagnostics. It is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. It operates in the Healthcare sector.

Lunai Bioworks Inc is not a good buy right now due to its current price of $0.1648, which is significantly down 97.88% year-to-date and 85.54% over the last 20 days. The RSI is extremely low at 6.305, indicating that the stock is oversold. Furthermore, the company has reported zero revenue for multiple quarters, and its gross margin is only 4.45% for the upcoming quarter, which is concerning for long-term viability. The main risk is the company's high debt levels, with a debt-to-equity ratio of -14829.67%, indicating severe financial distress.